Hyaluronan-binding peptide for targeting peritoneal carcinomatosis

Area of Science:

• Oncology
• Molecular Biology
• Nanotechnology

Background:

• Peritoneal carcinomatosis is a common metastasis from gastrointestinal and gynecological cancers.
• Treatment is difficult due to poor drug penetration into peritoneal micro-tumors.
• Targeted delivery systems are needed to overcome these challenges.

Purpose of the Study:

• To identify and validate a peptide that homes to peritoneal tumors.
• To assess the peptide's ability to deliver payloads to peritoneal metastases.
• To explore the peptide's potential for targeted cancer therapy.

Main Methods:

• In vivo phage display on a mouse model of gastric peritoneal carcinomatosis.
• High-throughput sequencing to identify peptide sequences.
• In vitro binding assays using hyaluronan.
• Intraperitoneal administration of labeled peptide in tumor-bearing mice.
• Functionalization of silver nanoparticles with the peptide.

Main Results:

• A novel tumor-homing peptide, CKRDLSRRC (IP3), was identified.
• IP3 peptide binds to hyaluronan and targets macrophage-rich regions in peritoneal tumors.
• IP3 peptide effectively homes to both vascularized and avascular micro-tumors.
• IP3-functionalized nanoparticles demonstrated homing to peritoneal tumors.

Conclusions:

• The IP3 peptide shows significant potential for targeting peritoneal metastases.
• It can facilitate the delivery of drugs, nanoparticles, and imaging agents to peritoneal tumors.
• IP3 represents a promising tool for improving peritoneal carcinomatosis treatment.